Physician profile
Anthony Dimura
NPI 1124520333
$129,932.63
in general payments reported to CMS, 2019-2025
28 companies · $36K in 2025
The $36K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $9,313 · 2023: $31K · 2024: $40K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Consulting Fee: $10K · Food and Beverage: $8,682 · Travel and Lodging: $5,700 · Honoraria: $5,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,083.25 |
| Consulting Fee | $10,488.00 |
| Food and Beverage | $8,681.74 |
| Travel and Lodging | $5,699.52 |
| Honoraria | $5,525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $56,487.73 | 2021-2025 | Spravato |
| Abbvie INC. | $31,992.21 | 2021-2025 | |
| Axsome Therapeutics, INC. | $18,956.25 | 2022-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $15,967.29 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,058.99 | 2021-2025 | Aristada, Lybalvi |
| Allergan, INC. | $825.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $774.81 | 2021-2025 | Caplyta |
| Lundbeck LLC | $626.34 | 2021-2025 | Rexulti |
| Indivior INC. | $432.29 | 2021-2025 | Sublocade, Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $413.17 | 2021-2024 | Trintellix |
| Braeburn INC. | $369.79 | 2023-2025 | Brixadi |
| Neurocrine Biosciences, INC. | $277.84 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $271.27 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Vanda Pharmaceuticals INC. | $243.49 | 2021-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $242.92 | 2021-2025 | Loreev Xr, Sertraline Hcl |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $182.76 | 2022-2024 | Azstarys |
| Bausch Health US, LLC | $174.08 | 2022-2025 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $144.57 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $119.89 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $72.79 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $72.71 | 2024-2025 | Cobenfy |
| Eisai INC. | $71.01 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $67.85 | 2022-2024 | Qelbree |
| Adlon Therapeutics L.P. | $27.12 | 2021 | |
| Neuronetics, INC. | $20.78 | 2023 | Neurostar Tms Therapy System |
| Neos Therapeutics, LP | $14.49 | 2022 | |
| Sage Therapeutics, LLC | $13.47 | 2024 | |
| Uswm, LLC | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Dimura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.